ANGIODYNAMICS INC (ANGO) Stock News
NASDAQ:ANGO - Nasdaq - US03475V1017 - Common Stock - Currency: USD
ANGO Latest News, Press Relases and Analysis
PacBio Stock Slips Despite New China Distribution Deal With Haorui
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
QGEN Stock Might Gain Following New Partnership With ID Solutions
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech
Autonomix secures key U.S. patent for its groundbreaking catheter-based nerve-sensing and stimulation tech, aiming to transform treatment across major diseases
Walgreens Opens New Micro-Fulfillment Center in Brooklyn Park
WBA expands micro-fulfillment with a new facility in Brooklyn Park, MN. This will support nearly 200 Walgreens stores across the Midwest.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
Exact Sciences ends the first quarter of 2025 on a solid note.
BAX Stock May Rise Following the Launch of FDA-Approved Hemopatch Pad
Baxter launches Hemopatch Sealing Hemostat, an FDA-approved collagen pad designed for effective hemostasis and sealing in both open and minimally invasive surgeries.
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market
MDT delivers strong fourth-quarter fiscal 2025 results, with significant improvements in both gross and operating margins.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System
Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.
Neogen Stock Gains Following Strategic Alliance With Syngenta
NEOG inks a new strategic licensing and supply agreement with Syngenta to market and sell the latter's Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada.
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL continues to gain from its robust product portfolio and strong segmental performance.
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Mentions: IDXX
Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered
ALC ends the first quarter of 2025 on a disappointing note.
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.
QIAGEN Stock Gains Following the Acquisition of Genoox
QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised
PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls
GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
Phibro Q3 Earnings Top Estimates, Stock Up, 2025 EPS Outlook Raised
PAHC's third-quarter fiscal 2025 results reflect the strength of the Animal Health segment.
Bruker Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Crash
Bruker delivers better-than-expected earnings and revenues in the first quarter of 2025.
EYE Q1 Earnings and Revenues Beat, Gross Margin Up, Stock Surges
Continued strength in Managed Care aids National Vision's first-quarter 2025 performance.
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut
IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.
NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash
Envista delivers better-than-expected top and bottom-line results for the first quarter of 2025.
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.
TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up
Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.